ArticleNanomaterials (Basel, Switzerland)2020
Freeze-Dried Softisan
Article in Nanomaterials (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 25 citations in OpenAlex.
- Strategies for transportation of peptides across the skin for treatment of multiple diseases.Therapeutic delivery · 2025Review
- Cyclosporin A-loaded dissolving microneedles for dermatitis therapy: Development, characterisation and efficacy in a delayed-type hypersensitivity in vivo model.Drug delivery and translational research · 2024Article
- Nanocarrier-Based Transdermal Drug Delivery Systems for Dermatological Therapy.Pharmaceutics · 2024Review
- Recent Advancements and Trends of Topical Drug Delivery Systems in Psoriasis: A Review and Bibliometric Analysis.International journal of nanomedicine · 2024Review
- Nanotechnology-based alternatives for the topical delivery of immunosuppressive agents in psoriasis.International journal of pharmaceutics · 2023Review
- Development of Lipid Nanoparticles Containing Omega-3-Rich Extract of MicroalgaFoods (Basel, Switzerland) · 2022Article
- A comprehensive review on possibilities of treating psoriasis using dermal cyclosporine.Drug delivery and translational research · 2022Review
- Nanocarriers as Active Ingredients Enhancers in the Cosmetic Industry-The European and North America Regulation Challenges.Molecules (Basel, Switzerland) · 2022Review
- Enhanced Skin Delivery of Therapeutic Peptides Using Spicule-Based Topical Delivery Systems.Pharmaceutics · 2021Article
- Nanostructured Lipid Carriers for the Formulation of Topical Anti-Inflammatory Nanomedicines Based on Natural Substances.Pharmaceutics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Inflammatory skin diseases, including psoriasis and atopic dermatitis, affect around one quarter to one third of the world population. Systemic cyclosporine A, an immunosuppressant agent, is included in the current therapeutic armamentarium of these diseases. Despite being highly effective, it is associated with several side effects, and its topical administration is limited by its high molecular weight and poor water solubility. To overcome these limitations, cyclosporine A was incorporated into solid lipid nanoparticles obtained from Softisan
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.